Proboka Guna, Tilgase Andra, Isajevs Sergejs, Rasa Agnija, Alberts Pēteris
Latvian Oncology Centre, Riga Eastern Clinical University Hospital, Riga, Latvia.
R&D, International Virotherapy Center, Riga, Latvia.
Front Oncol. 2018 Feb 26;8:43. doi: 10.3389/fonc.2018.00043. eCollection 2018.
Melanoma is considered an aggressive malignancy with a tendency of forming metastasis in the brain. Less than 10% of all melanoma cases present with unknown primary tumor location. This diagnose is yet to be fully understood, because there are only theoretical assumptions about the nature of the disease. Melanoma brain metastases have many severe side effects and, unfortunately, any disease related to the brain has limited therapeutic options due to the blood-brain barrier. The course of the disease after a treatment course is complicated to predict, and it is difficult to obtain long-lasting remission. In this report, we describe a female patient with unknown primary melanoma brain metastasis treated with the oncolytic ECHO-7 virus Rigvir after brain surgery. The patient has been stable, as monitored by magnetic resonance imaging, for more than 3.8 years with ongoing therapy. The median expected overall survival from the time of diagnosis is approximately 5 months. Additional positive effect could have been gained from use of the intranasal administration route, which is considered effective due to the direct anatomical connection between the nasal cavity and the central nervous system. However, further studies are required to fully understand this mode of drug administration.
黑色素瘤被认为是一种侵袭性恶性肿瘤，有在脑部形成转移的倾向。所有黑色素瘤病例中，不到10%的患者原发性肿瘤位置不明。这种诊断尚有待充分理解，因为对于该疾病的本质只有理论上的假设。黑色素瘤脑转移有许多严重的副作用，不幸的是，由于血脑屏障，任何与脑部相关的疾病治疗选择都有限。一个疗程治疗后的疾病进程难以预测，且难以获得持久缓解。在本报告中，我们描述了一名原发性不明的黑色素瘤脑转移女性患者，在脑部手术后接受溶瘤ECHO - 7病毒Rigvir治疗。通过磁共振成像监测，该患者在持续治疗下已稳定超过3.8年。从诊断时起的预期中位总生存期约为5个月。使用鼻内给药途径可能会产生额外的积极效果，由于鼻腔与中枢神经系统之间存在直接的解剖学联系，鼻内给药途径被认为是有效的。然而，需要进一步研究来充分理解这种给药方式。
